SCHEMBL2188117

SCHEMBL2188117

CC(C)([C@@H]1CCN(c2ccc(C(F)(F)F)cn2)C(=O)C1)S(=O)(=O)c1cc(F)cc(C(F)(F)F)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.40
GPR119 Q8TDV5 1/20 0.40
NR1I2 O75469 1/20 0.39
CYP3A4 P08684 1/20 0.39
CACNA1B Q00975 1/20 0.39
HCRTR1 O43613 1/20 0.38
HCRTR2 O43614 1/20 0.38
NR1H2 P55055 4/20 0.38
NR1H3 Q13133 4/20 0.38
KDM4E B2RXH2 2/20 0.38
ABL1 P00519 1/20 0.38
LMNA P02545 1/20 0.38
SMO Q99835 1/20 0.38
APAF1 O14727 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2193112 1.00 PKM (0.40) PKMGPR119NR1I2CYP3A4CACNA1B
SCHEMBL7920460 0.89 CYP3A4 (0.46) GPR119NR1I2CYP3A4CACNA1BHCRTR1
SCHEMBL2196073 0.89 CYP3A4 (0.46) GPR119NR1I2CYP3A4CACNA1BHCRTR1
SCHEMBL2189730 0.89 CYP3A4 (0.46) GPR119NR1I2CYP3A4CACNA1BHCRTR1
SCHEMBL2189697 0.84 DPP4 (0.43) GPR119NR1I2CYP3A4CACNA1BNR1H2
SCHEMBL2187292 0.84 DPP4 (0.43) GPR119NR1I2CYP3A4CACNA1BNR1H2
Trifluoroacetic Acid SCHEMBL2189660 0.84 CYP3A4 (0.46) PKMGPR119NR1I2CYP3A4CACNA1B
SCHEMBL2190550 0.82 CACNA1B (0.44) GPR119NR1I2CYP3A4CACNA1BHCRTR1
SCHEMBL2189349 0.82 CACNA1B (0.44) GPR119NR1I2CYP3A4CACNA1BHCRTR1
SCHEMBL2188044 0.81 CACNA1B (0.51) GPR119NR1I2CYP3A4CACNA1BNR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US claimed
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US disclosed
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US disclosed
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS TRPV1, TRPA1, CACNA1D PKM 4019/4885GPR119 136/4885NR1I2 765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.